Edgewise Therapeutics to Participate in Upcoming Investor Conferences

Core Insights - Edgewise Therapeutics, Inc. is a leading biopharmaceutical company focused on developing novel therapeutics for muscle diseases and serious cardiac conditions [2][3]. Group 1: Investor Conferences - Management will participate in multiple investor conferences, including the Guggenheim 2nd Annual Healthcare Innovation Conference on November 11, 2025, at 8:30 am ET, the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025, at 2 pm ET, and the 8th Annual Evercore Healthcare Conference on December 3, 2025, at 3:25 pm ET [1]. Group 2: Product Development - Sevasemten is an orally administered first-in-class fast skeletal myosin inhibitor in late-stage clinical trials for Becker and Duchenne muscular dystrophies [2]. - EDG-7500 is a novel cardiac sarcomere modulator for treating hypertrophic cardiomyopathy and other diseases of diastolic dysfunction, currently in Phase 2 clinical development [2]. - EDG-15400 is another cardiac sarcomere modulator for heart failure, currently in Phase 1 clinical development [2]. Group 3: Company Mission - The company is dedicated to changing the lives of patients and families affected by serious muscle diseases [2].